A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Sep 2017 Planned End Date changed from 1 Jan 2021 to 1 Mar 2020.
- 02 Jun 2017 Status changed from active, no longer recruiting to discontinued, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.